jueves, 19 de noviembre de 2026
After a GLP-1: Which Exit Strategy Keeps the Weight Off?
https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh?ecd=WNL_trdalrt_pos1_ous_261118_etid8915401&uac=148436CN&impID=8915401
NATIONAL HARBOR, Md. — Among more than 20,000 patients who had taken semaglutide or tirzepatide, those who went on to pursue bariatric surgery, though the least likely choice, had the greatest weight loss after 2 years, while those who stopped treatment altogether had the least, new data show.
“To our knowledge, this is the first study to compare weight change and cardiometabolic parameters across several obesity treatment strategies in patients who initially took injectable semaglutide or tirzepatide for obesity or type 2 diabetes,” Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, told Medscape Medical News.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario